The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review

The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review

<i>Background and Objectives:</i> The association between diabetes mellitus and increased risk of bone fractures has led to the investigation of the impact of antidiabetic drugs on bone metabolism. Glucagon-like peptide-1 receptor agonists (GLP1RAs) are a relatively novel and promising c...

Full description

Bibliographic Details
Main Authors:	Ioanna Daniilopoulou, Eugenia Vlachou, George I. Lambrou, Anastasia Ntikoudi, Eleni Dokoutsidou, Georgia Fasoi, Ourania Govina, Anna Kavga, Athanasios N. Tsartsalis
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Medicina
Subjects:	GLP GLP1RAs bone mineral density diabetes mellitus
Online Access:	https://www.mdpi.com/1648-9144/58/2/224

Similar Items

Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
by: Yolanda Diz-Chaves, et al.
Published: (2022-08-01)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
by: Chudleigh RA, et al.
Published: (2020-02-01)

Anti-Inflammatory Effects of GLP-1R Activation in the Retina
by: Alessandra Puddu, et al.
Published: (2022-10-01)

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
by: Kallirhoe Kalinderi, et al.
Published: (2024-03-01)

Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?
by: Dalgisio Lecis, et al.
Published: (2023-11-01)

Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system
by: Sarina Gadgaard, et al.
Published: (2023-04-01)

HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity
by: P.P. Mohanan, et al.
Published: (2023-01-01)

Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials
by: Sijin Wu, et al.
Published: (2022-12-01)

GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
by: Eleonora Panfili, et al.
Published: (2023-06-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study
by: Chih-Yiu Tsai, et al.
Published: (2022-01-01)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
by: Amisha Wallia, et al.
Published: (2023-05-01)

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study
by: Salvatore Greco, et al.
Published: (2023-08-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

Analogos de GLP1: marcando nuevas rutas en el manejo de la diabetes
by: Luz Angela Casas Figueroa
Published: (2022-06-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

TXNIP reduces pro-proliferation effect of GLP-1 on mouse islet β cells
by: ZHANG Wen-ting, WANG Jin, YUE Ji-ping, JIN Wen-wen, ZHANG Zhi-nan, JIAO Xiang-ying
Published: (2020-08-01)

Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
by: Sudhir Pandey, et al.
Published: (2023-06-01)

Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
by: Hong Li, et al.
Published: (2024-02-01)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023-02-01)

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
by: Juan Pang, et al.
Published: (2022-11-01)

Fatigue among Patients with Type 2 Diabetes Mellitus: The Impact of Spirituality and Illness Perceptions
by: Maria Vasilaki, et al.
Published: (2023-12-01)

Berberine enhances the function of db/db mice islet β cell through GLP-1/GLP-1R/PKA signaling pathway in intestinal L cell and islet α cell
by: Wenbin Wu, et al.
Published: (2023-07-01)

Editorial: Incretin agonists in the treatment of obesity
by: Xiaodong Sun, et al.
Published: (2023-08-01)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Heeyoung Lee, et al.
Published: (2021-09-01)

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
by: Sydney S. Wilbon, et al.
Published: (2023-12-01)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022-09-01)

GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report
by: Fionnuala Crowley, et al.
Published: (2024-04-01)

Genetic Evidence for Repurposing of GLP1R (Glucagon‐Like Peptide‐1 Receptor) Agonists to Prevent Heart Failure
by: Iyas Daghlas, et al.
Published: (2021-07-01)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
by: José Luis Górriz, et al.
Published: (2020-03-01)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
by: Rasmus Stenlid, et al.
Published: (2023-11-01)

GLP-1 Receptor Agonist Improves Mitochondrial Energy Status and Attenuates Nephrotoxicity In Vivo and In Vitro
by: Linxi Wang, et al.
Published: (2023-11-01)

GLP1 Exerts Paracrine Activity in the Intestinal Lumen of Human Colon
by: Carme Grau-Bové, et al.
Published: (2022-03-01)

Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
by: Mohammed A. Al-Sadawi, et al.
Published: (2023-08-01)

GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
by: Alessio Mazzieri, et al.
Published: (2023-11-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
by: Jianxing Zhou, et al.
Published: (2024-02-01)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
by: Bo Ahrén
Published: (2023-02-01)

The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
by: Teodor Salmen, et al.
Published: (2023-03-01)

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
by: Mihaela-Simona Popoviciu, et al.
Published: (2023-06-01)